Weight Loss

Recent data revealed that individually targeted obesity interventions guided by phenotypes can double weight loss compared with usual care. This was the top story in endocrinology last week.

Some weight loss and sports supplements sold in the United States that listed deterenol as an ingredient also contained “prohibited” and possibly dangerous stimulants, researchers wrote in Clinical Toxicology.

Phenotype-guided obesity interventions, determined by a blood test, can double weight loss for patients compared with standard obesity care, according to a presenter at the Obesity Medicine Association 2021 virtual conference.

Deprescribing medications can benefit patients with obesity, but providers must use caution to avoid hypoglycemia or hypertension for those with diabetes, according to a speaker.

Adults with obesity may have more success with weight loss by engaging in inefficient behaviors, according to a presenter at the Obesity Medicine Association 2021 virtual conference.

Rapid weight gain and loss are linked with a high risk of adverse outcomes in patients with chronic kidney disease, according to a study.

Adults with type 2 diabetes who have an elevated BMI at diagnosis are at increased risk for microvascular complications, although the risk can be reduced with weight loss, according to a study published in Diabetologia.

Exercise provided considerable weight loss-independent benefits in patients with nonalcoholic fatty liver disease, according to research published in JHEP Reports.

The American Gastroenterological Association published new clinical practice guidelines on the use of intragastric balloons in obesity management.

First tweet: At 10 years of follow-up, 50% of a group of patients who underwent biliopancreatic diversion and 25% who had Roux-en-Y gastric bypass experienced diabetes remission vs. 5.5% who received medical therapy. @GeltrudeMingro2 @TheLancet